HeFi-1

HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for researches on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma[1][2].

Product Specifications

UNSPSC

12352203

Target

Apoptosis; TNF Receptor

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

References & Citations

[1]Zhang M, et al. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood. 2006 Jul 15;108 (2) :705-10.|[2]Berro AI, et al. Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol. 2004 Aug 1;173 (3) :2174-83.